drugset / Trial / NCT01699022

Pharmacokinetic and Pharmacodynamic Study of Cyclofem

NCT01699022

Phase 1/2 Completed 17 enrolled Sun Pharmaceutical Industries, Inc.
NaSingle-groupOpen-labelPrevention

Summary

Cyclofem® is a monthly injectable contraceptive containing 25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate (E2C), a long-acting ester of estradiol. The current study will assess the steady-state pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate (MPA) and estradiol (E2) after administration of Cyclofem® and will provide critical information to determine similar bioavailability of Cyclofem to Lunelle in women residing in the United States of America.

Timeline

Start
2010-06
Primary completion
2011-07
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Cypionate Small molecule 5 mg Other
Subject medroxyprogesterone acetate Other / unclassified 25 mg Other

Indications

No indication recorded.